GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles
Résumé
Highlights d Implementation hurdles restrict adoption of HRD testing, a PARPi response biomarker d GIInger leverages HRD-induced genome scarring from lowcoverage sequencing data d GIInger accurately stratifies ovarian cancer patients for PARPi treatment d GIInger is cost effective and seamlessly integrates into BRCA status workflows Authors
Domaines
Cancer| Origine | Fichiers éditeurs autorisés sur une archive ouverte |
|---|